Takeda Pharmaceutical Co Ltd (TKPHF) Cash & Current Investments (2017 - 2026)

Takeda Pharmaceutical's Cash & Current Investments history runs 10 years deep, the most recent figure standing at $5.8 billion for Q2 2026.

• In Q2 2026, Cash & Current Investments rose 22.08% year-over-year to $5.8 billion; the TTM figure through Jun 2026 stood at $5.8 billion (up 22.08% YoY), while the FY2026 annual figure was $6.9 billion, up 158.23% from the prior year.
• Cash & Current Investments for Q2 2026 stood at $5.8 billion, down from $6.6 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $8.2 billion in Q3 2022, with the low at $2.7 billion in Q1 2025.
• The 5-year median for Cash & Current Investments is $6.2 billion (2024), against an average of $5.8 billion.
• The sharpest annual moves came in 2023 and 2026: Cash & Current Investments plunged 46.43% in 2023, then jumped 148.25% in 2026.
• Takeda Pharmaceutical's Cash & Current Investments stood at $6.8 billion in 2022, then sank by 44.46% to $3.8 billion in 2023, then surged by 55.37% to $5.9 billion in 2024, then climbed by 19.53% to $7.0 billion in 2025, then fell by 17.3% to $5.8 billion in 2026.
• Business Quant data shows TKPHF's Cash & Current Investments at $5.8 billion in Q2 2026, $6.6 billion in Q1 2026, and $7.0 billion in Q4 2025.